Cleo Diagnostics (ASX:COV) LT-Debt-to-Total-Asset: 0.00 (As of Dec. 2025)


ASX:COV Cleo Diagnostics Ltd ASX:COV
17 GF Score
Price A$0.48
! 1 Warning Sign
View Full Analysis

What is Cleo Diagnostics LT-Debt-to-Total-Asset?

Cleo Diagnostics ASX:COV -3.03% 17 LT-Debt-to-Total-Asset is 0.00 as of Dec. 2025. GuruFocus rates ASX:COV with a GF Score™ of 17/100. The stock has 1 warning sign investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Cleo Diagnostics's long-term debt to total assests ratio for the quarter that ended in Dec. 2025 was 0.00.

Cleo Diagnostics's long-term debt to total assets ratio stayed the same from Dec. 2024 (0.00) to Dec. 2025 (0.00).

Cleo Diagnostics  (ASX:COV) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Cleo Diagnostics LT-Debt-to-Total-Asset Related Terms

Cleo Diagnostics LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Cleo Diagnostics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cleo Diagnostics LT-Debt-to-Total-Asset Chart

Cleo Diagnostics Annual Data
Trend Jun23 Jun24 Jun25
LT-Debt-to-Total-Asset
0.00 0.00 0.00

Cleo Diagnostics Semi-Annual Data
Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
LT-Debt-to-Total-Asset Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
ASX:COV
17GF Score
Cleo Diagnostics Ltd ASX:COV
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cleo Diagnostics LT-Debt-to-Total-Asset Calculation

Cleo Diagnostics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Jun. 2025 is calculated as

LT Debt to Total Assets (A: Jun. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Jun. 2025 )/Total Assets (A: Jun. 2025 )
=0/6.936
=

Cleo Diagnostics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (Q: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2025 )/Total Assets (Q: Dec. 2025 )
=0/9.961
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.00 mean?
Cleo Diagnostics (ASX:COV) has a LT-Debt-to-Total-Asset of 0.00 as of Dec. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Cleo Diagnostics and its competitors.
Is Cleo Diagnostics' LT-Debt-to-Total-Asset too high?
Cleo Diagnostics' current LT-Debt-to-Total-Asset is 0.00. Overall, Cleo Diagnostics has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Cleo Diagnostics' LT-Debt-to-Total-Asset compare to ABT and SYK?
Cleo Diagnostics' LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Medical Devices & Instruments company?
A good LT-Debt-to-Total-Asset depends on the Medical Devices & Instruments industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Cleo Diagnostics and its competitors. Cleo Diagnostics's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cleo Diagnostics stock overvalued right now?
Cleo Diagnostics (ASX:COV) has a current LT-Debt-to-Total-Asset of 0.00. The current LT-Debt-to-Total-Asset is 0.00. Cleo Diagnostics' overall GF Score™ is 17/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Cleo Diagnostics (ASX:COV), the current LT-Debt-to-Total-Asset is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cleo Diagnostics Business Description

Address 480 Collins Street, Level 2, Melbourne, VIC, AUS, 3000
Cleo Diagnostics Ltd is focused on the development of non-invasive blood-based IVD tests to detect the presence, and recurrence, of ovarian cancer. The company's first product to market is intended to be the Triage Test which results to accurately differentiate patients with malignant ovarian cancer from those with benign gynecological conditions. The company aims to improve the diagnostic process and procedures for detecting ovarian cancer and, in this regard, improve quality-of-life outcomes for patients who have been diagnosed with ovarian cancer.
17GF Score

Get the complete analysis for ASX:COV

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.48
Price